121306_Monoamine transporters.pdf (552.44 kB)
Monoamine transporters: vulnerable and vital doorkeepers
journal contribution
posted on 2023-05-19, 11:19 authored by Lin, Z, Canales, JJ, Bjorgvinsson, T, Thomsen, M, Qu, H, Liu, Q-R, Torres, GE, Caine, SBTransporters of dopamine, serotonin, and norepinephrine have been empirically used as medication targets for several mental illnesses in the last decades. These protein-targeted medications are effective only for subpopulations of patients with transporter-related brain disorders. Since the cDNA clonings in early 1990s, molecular studies of these transporters have revealed a wealth of information about the transporters' structure-activity relationship (SAR), neuropharmacology, cell biology, biochemistry, pharmacogenetics, and the diseases related to the human genes encoding these transporters among related regulators. Such new information creates a unique opportunity to develop transporter-specific medications based on SAR, mRNA, DNA, and perhaps transporter trafficking regulation for a number of highly relevant diseases including substance abuse, depression, schizophrenia, and Parkinson's disease.
History
Publication title
Progress in molecular biology and translational scienceVolume
98Pagination
1-46ISSN
1877-1173Department/School
School of Psychological SciencesPublisher
Elsevier/APPlace of publication
NetherlandsRights statement
Copyright 2011 ElsevierRepository Status
- Open